Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

NCT: NCT07333183 · RECRUITING

NCT IDNCT07333183
StatusRECRUITING
Start Date2025-12-23
SponsorPulmovant, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a background inhaled treprostinil.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑